OSAKA, Japan & CAMBRIDGE, Mass. - Wednesday, 27. March 2024
(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024.
Mr. Milano Furuta, currently president of the Japan Pharma Business Unit (JPBU), will succeed Mr. Constantine Saroukos as chief financial officer (CFO) effective April 1, 2024. Takeda will propose Mr. Furuta as a new candidate for board director at the Ordinary General Meeting of Shareholders. If approved by shareholders, Mr. Furuta will join the Board effective June 26, 2024.
Mr. Constantine Saroukos, who expressed his intention to retire as CFO, will leave the Board on June 26, 2024 upon the expiration of his term.
|
Candidates for Directors Who Are Not Audit and Supervisory Committee Members |
|||
|
Name |
Category |
Expected Role |
|
|
Christophe Weber |
Internal |
Existing |
Representative Director, President & Chief Executive Officer |
|
Andrew Plump |
Internal |
Existing |
Director, President, Research & Development |
|
Milano Furuta |
Internal |
New |
Director, Chief Financial Officer |
|
Masami Iijima |
External |
Existing |
External Director, Chair of the Board Meeting |
|
Olivier Bohuon |
External |
Existing |
External Director |
|
Ian Clark |
External |
Existing |
External Director |
|
Steven Gillis |
External |
Existing |
External Director |
|
John Maraganore |
External |
Existing |
External Director |
|
Michel Orsinger |
External |
Existing |
External Director |
|
Miki Tsusaka |
External |
Existing |
External Director |
|
Emiko Higashi |
External |
New |
External Director |
|
The tenure for non-Audit and Supervisory Committee director is one year. |
|||
|
Candidates for Directors Who Are Audit and Supervisory Committee Members |
|||
|
Name |
Category |
Expected Role |
|
|
Koji Hatsukawa |
External |
Existing |
External Director, Audit and Supervisory Committee Member |
|
Yoshiaki Fujimori |
External |
Existing |
External Director, Audit and Supervisory Committee Member |
|
Kimberly A. Reed |
External |
Existing |
External Director, Audit and Supervisory Committee Member |
|
Jean-Luc Butel |
External |
New |
External Director, Audit and Supervisory Committee Member |
|
The tenure for Audit and Supervisory Committee director is two years. |
|||
Note:
- The role of the directors will be determined at the Board of Directors meeting and the Audit and Supervisory Committee meeting to be held after the 148th Ordinary General Meeting of Shareholders.
- The members of the Nomination Committee and Compensation Committee will be discussed and determined at the Board of Directors meeting to be held after the 148th Ordinary General Meeting of Shareholders.
- Ms. Asuka Miyabashira, currently head of the Neuroscience Business Unit within JPBU, will assume the role of president of JPBU, effective April 1, 2024.
About Takeda
Takeda is focused on creating better health for people and a brighter
future for the world. We aim to discover and deliver life-transforming
treatments in our core therapeutic and business areas, including
gastrointestinal and inflammation, rare diseases, plasma-derived
therapies, oncology, neuroscience and vaccines. Together with our
partners, we aim to improve the patient experience and advance a new
frontier of treatment options through our dynamic and diverse pipeline.
As a leading values-based, R&D-driven biopharmaceutical company
headquartered in Japan, we are guided by our commitment to patients, our
people and the planet. Our employees in approximately 80 countries and
regions are driven by our purpose and are grounded in the values that
have defined us for more than two centuries. For more information, visit
www.takeda.com.
Important Notice
For the purposes of this notice, “press release” means this document,
any oral presentation, any question and answer session and any written
or oral material discussed or distributed by Takeda Pharmaceutical
Company Limited (“Takeda”) regarding this release. This press release
(including any oral briefing and any question-and-answer in connection
with it) is not intended to, and does not constitute, represent or form
part of any offer, invitation or solicitation of any offer to purchase,
otherwise acquire, subscribe for, exchange, sell or otherwise dispose
of, any securities or the solicitation of any vote or approval in any
jurisdiction. No shares or other securities are being offered to the
public by means of this press release. No offering of securities shall
be made in the United States except pursuant to registration under the
U.S. Securities Act of 1933, as amended, or an exemption therefrom. This
press release is being given (together with any further information
which may be provided to the recipient) on the condition that it is for
use by the recipient for information purposes only (and not for the
evaluation of any investment, acquisition, disposal or any other
transaction). Any failure to comply with these restrictions may
constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments
are separate entities. In this press release, “Takeda” is sometimes used
for convenience where references are made to Takeda and its
subsidiaries in general. Likewise, the words “we”, “us” and “our” are
also used to refer to subsidiaries in general or to those who work for
them. These expressions are also used where no useful purpose is served
by identifying the particular company or companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321811422/en/
Contacts
Media Contacts:
Global Media
Brendan Jennings
brendan.jennings@takeda.com
+81 80-2705-8259
